Early Portfolio Decisions
Evaluate and prioritize opportunities with AI-powered diligence
K Pro enables end-to-end AI-powered evaluation of early-stage opportunities. From target biology and developability assessment, to benchmarking against clinical landscapes, K Pro gives you the confidence to invest in programs with the highest probability of success.
Solving actual pharma R&D challenges in minutes
Target Selection
We have bulk RNA-Seq showing promising expression, but our team needs the multimodal and spatial data and specialized AI to understand how our target behaves in the actual tumor microenvironment before we commit resources to this program.
Translational Lead, Oncology
Gain confidence to advance your asset or program based on data
Understand your immune target within the competitive landscape, the ideal patient population, and the biomarkers to enrich for responders selection. Read Case Study
Portfolio & In-Licensing Evaluation
We're evaluating an asset for potential in-licensing. We need to rapidly assess the competitive landscape, understand real-world treatment patterns, and identify gaps in the data package before we commit to due diligence.
VP Portfolio Strategy, Oncology
Make confident, data-driven in-licensing decisions
Assess asset value and competitive positioning with AI-powered landscape analysis and real-world evidence. Gain clear understanding of data gaps, safety signals, and commercial opportunities
Ready to get started?
Discover how K Pro can transform your drug discovery and development. Connect with our team to explore how we can support your specific needs.
